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There is broad evidence that lowering low-density lipoprotein (LDL) cholesterol will reduce cardiovascular risk. However, in patients on
maintenance hemodialysis treatment, lowering LDL cholesterol is not as effective in preventing cardiovascular complications as in the
general population. Cholesterol is either endogenously synthesized or absorbed from the intestine. It has been suggested that the
benefit of using statins to prevent atherosclerotic complications is less pronounced in people with high absorption of cholesterol. Recent
data indicate that patients on hemodialysis have high absorption of cholesterol. Therefore, these patients may benefit from dietary coun-
seling to reduce cholesterol intake, from functional foods containing plant sterols and stanols, and from drugs that interfere with intes-
tinal absorption of sterols (i.e., ezetimibe, bile acid resins, and sevelamer). This review discusses cholesterol homeostasis and the
perspective of personalized treatment of hypercholesterolemia in hemodialysis.
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HYPERCHOLESTEROLEMIA IS AMONG themain risk factors for atherosclerotic vascular disease.1,2
However, in patients on maintenance hemodialysis treat-
ment, the relationship between circulating cholesterol
and vascular endpoints appears to be less consistent.3 A
large-scale Japanese study has indeed reported multivariate-
adjusted, positive correlations of non-high-density lipopro-
tein (HDL) and low-density lipoprotein (LDL) cholesterol
levels with incident myocardial infarction.4 However, an
unadjusted inverse relationship between total cholesterol
and all-cause death was reported in the same cohort.4 In-
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inverse relationships of total cholesterol with all-cause death
and the less pronounced positive associations of non-HDL
and LDL cholesterol levels with vascular endpoints are most
likely caused by malnutrition, protein-energy wasting, and
frailty, which are prevalent in end-stage renal disease.4-6
Nevertheless, LDL in patients on chronic hemodialysis is
considered harmful because of the accumulation of
particularly atherogenic LDL subfractions.7
There is broad evidence that lowering LDL cholesterol
will reduce cardiovascular mortality in the general popula-
tion.8-10 However, the effectiveness of statin treatment to
prevent cardiovascular complications is less evident in
hemodialysis.11,12 In the 1,255 participants of the 4D
study, 20 mg of atorvastatin did not reduce the primary
endpoint compared with placebo.11 Moreover, 10 mg of
rosuvastatin had no significant effects on cardiovascular
events in the 2,776 participants of the AURORA trial.12
The work presented here aims to discuss cholesterol
homeostasis in chronic dialysis patients and potential im-
plications of cholesterol homeostasis for lipid-lowering
treatment. Moreover, different strategies of cholesterol-
lowering treatment with a focus on therapies targeting in-
testinal cholesterol absorption are reviewed.Cholesterol Homeostasis
Circulating cholesterol is derived from diet or from
endogenous de novo synthesis.13 Intestinal absorption of
cholesterol is a multistep process.14 Cholesterol and plant
sterols are taken up into enterocytes after hydrolysis by
lipases in mixed micelles together with bile acids and other
lipids (Fig. 1).14 The Niemann Pick C1-like 1 (NPC1L1)
protein is crucial in the process of internalization of micelles
into the enterocyte brush border (Fig. 1).14 The ATP65
Figure 1. Cholesterol homeostasis with a focus on the intestine and the liver with contact points of different LDL cholesterol-
lowering strategies that affect the absorption of sterols. 1. Reduced dietary intake of cholesterol. 2. Reduction of cholesterol con-
tent of mixedmicelles due to the use of plant sterols. 3. Reduced solubilization of cholesterol in mixedmicelles by bile acid resins
and sevelamer. 4. Inhibition of NPC1L1mediated cholesterol uptake by ezetimibe. ABCA1, ATP binding cassette transporter A1;
ABCG5/8, ATP binding cassette co-transporters G5 and G8; ACAT2, acetylcoenzyme-A cholesterol acyl transferase 2; CM,
chylomicron; HDL, high-density lipoprotein; LDL-R, low-density lipoprotein receptor; MTP, microsomal triglyceride transfer pro-
tein; NPC1L1, Niemann Pick C1-like 1 protein; SRBI, scavenger receptor class B type 1.
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ABCG8) re-secrete cholesterol and plant sterols, that have
not been esterified by acetyl-coenzyme-A cholesterol
acyl transferase 2, back from the enterocyte into the intes-
tinal lumen (Fig. 1).14 Because most of cholesterol is ester-
ified, whereas plant sterols are poorly esterified,
re-secretion is much higher for plant sterols than for choles-
terol. Hence, approximately 50% of intestinal cholesterol,
but only 1% to 2% of plant sterols, are finally incorporated
into chylomicrons or HDL and leave the enterocyte at the
basolateral membrane via lymph (Fig. 1).14 Incorporation
of cholesterol into lipoproteins is mediated by the micro-
somal triglyceride transfer protein and the ATP binding
cassette transporter A1 (Fig. 1).14 The LDL receptor and
scavenger receptor class B type 1 are involved in the uptake
of cholesterol and plant sterols from chylomicrons and
HDL, respectively, into the liver (Fig. 1).14
Recent genome-wide association studies have shown
variants in the ATP binding cassette transporter G8
(ABCG8) andABO genes to consistently correlate with in-
testinal cholesterol absorption and consecutive changes in
cholesterol synthesis.15 In addition to genetic regulation,
cholesterol absorption and synthesis are influenced bymetabolic factors.13,16,17 For example, obesity, type 2
diabetes, and fatty liver predispose to high synthesis and
low absorption of cholesterol.16-18 On the other hand,
type 1 diabetes and frailty are associated with low synthesis
and high absorption of cholesterol.17,19 Age appears to be
inversely related to cholesterol absorption and
synthesis.16,17 Taken together, the balance of cholesterol
absorption and synthesis is individually regulated. In
general, cholesterol absorption and synthesis are
interrelated so that people with high cholesterol
absorption display low cholesterol synthesis and vice
versa.16,17 Using stable isotope methods, circulating
noncholesterol sterols and cholestanol have been
demonstrated to indicate cholesterol absorption and
synthesis.20,21 The association with cholesterol homeostasis
measured with isotope methods was even stronger for the
ratios of the noncholesterol sterols and cholestanol to
cholesterol than for the uncorrected values.20,21 Several
methods, which are based on gas chromatography,
gas-liquid chromatography, and/or mass spectrometry,
have been developed to analyze these compounds.17,22
Circulating campesterol and sitosterol, representing the 2
most abundant plant sterols, can be used to estimate
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circulating plant sterols is that they also reflect the fruit and
vegetable content of the diet.13,20 This may confound
associations of cholesterol homeostasis with vascular
disease.23 Circulating cholestanol, which is structurally
highly similar to cholesterol, can be used instead of plant
sterols to estimate cholesterol absorption.13,21,23 In
contrast to circulating plant sterols, cholestanol does not
increase in response to high intake of plant-derived
foods.23 Circulating lathosterol, which is a cholesterol
precursor, is most commonly used to estimate cholesterol
synthesis.13,20 Such as cholesterol, noncholesterol sterols
and cholestanol are transported in the blood stream as
components of lipoproteins.24 Most noncholesterol ste-
rols and cholestanol in the circulation are carried in
LDL particles. However, they can also be found in other
lipoprotein subfractions, with cholestanol and plant ste-
rols being abundant in HDL and lathosterol being abun-
dant in very-low-density lipoprotein.24
Efficacy of Lipid-Lowering Strategies
Depends on Cholesterol Metabolism
Hypercholesterolemia may be due to increased choles-
terol absorption, increased cholesterol synthesis, or both.13
On the basis of this pathophysiology, there are 2 main
concepts to treat hypercholesterolemia. Firstly, cholesterol
synthesis may be reduced with statins.8-10 Secondly,
cholesterol absorption may be reduced with a diet low in
cholesterol,25,26 with plant sterols or stanol-enriched func-
tional foods,27 orwith drugs interferingwith cholesterol ab-
sorption.14,28,29 There is some evidence that the individual
balance of cholesterol absorption and synthesis has an effect
on the response to lipid-lowering treatment.30-32 For
example, inhibition of cholesterol synthesis with statins
appears to be less effective in people with high cholesterol
absorption.30,33 In contrast, inhibition of cholesterol
absorption with ezetimibe, plant sterols, or stanols appears
to be less efficient in people with low cholesterol
absorption.31,32 Dietary interventions and the use of other
cholesterol absorption inhibitors such as bile acid resins
and sevelamer should also be more effective in high
cholesterol absorbers compared with high cholesterol
synthesizers.
Drugs Interfering With Intestinal
Cholesterol Handling
Ezetimibe
By binding to NPC1L1, ezetimibe inhibits the vesicular
internalization of this molecule, which is a crucial step in
intestinal cholesterol absorption.14,34 Reduced cholesterol
absorption in patients treated with ezetimibe is partly
compensated for by an increase of cholesterol synthesis.35
Nevertheless, 10 mg ezetimibe is associated with a decrease
in LDL cholesterol of approximately 15% when used as
monotherapy or in combination with a statin.34,36,37 Inaddition to LDL cholesterol, circulating plant sterols are
significantly reduced by treatment with ezetimibe.38
Therefore, ezetimibe is also used to treat patients with sitos-
terolemia.39 The question whether inhibition of sterol ab-
sorption with ezetimibe treatment will reduce
cardiovascular risk in the general population has so far
not been convincingly answered. However, the ongoing
IMPROVE-IT trial is being performed to answer the latter
question.40 The results of this study are expected to be pub-
lished in 2014.32
Bile Acid Resins
Bile acids, mainly cholic acid and chenodeoxycholic
acid, are synthesized in the liver and are excreted via
bile.34,41 Approximately 90% of bile salts are reabsorbed
in the ileum and colon.34,41 Bile acid resins bind bile
salts in the intestine, resulting in decreased reabsorption
of bile acids.34,41 In consequence, there is a need for
increased production of bile acids from cholesterol. This
leads to decreased intracellular cholesterol in the liver
and increased uptake of LDL cholesterol by the liver,
thereby reducing LDL cholesterol concentrations.34,41
Cholestyramine and colestipol are the 2 traditional bile
acid resins used for lowering cholesterol.41 Cholestyr-
amine is slightly more potent than colestipol, with 10 g
per day reducing LDL cholesterol as monotherapy or
in combination with statins by approximately 15%.41
Colesevelam is a novel bile acid resin that shows
markedly increased potency compared with the 2 afore-
mentioned bile acid resins. Of relevance, bile acid resins
have been demonstrated to prevent progression of athero-
sclerosis42 and to prevent cardiovascular events and
cardiovascular mortality in a randomized controlled
study.43 However, today cholestyramine and colestipol
are hardly used anymore for lowering cholesterol because
their intake frequently causes gastrointestinal side effects
(e.g., nausea, gastrointestinal discomfort).41 However,
the novel bile acid resin colesevelam appears to have fewer
side effects.41
Sevelamer
Sevelamer is a phosphate-lowering resin that has been
developed from colesevelam; therefore, it does not contain
calcium.44 Probably because of its bile acid binding prop-
erty,44 the use of sevelamer is associated with a decrease
of LDL cholesterol of approximately 30%.45 In a subgroup
analysis in European participants in the TTG-Study, seve-
lamer was associated with less progression of aortic and cor-
onary calcification compared with calcium-containing
agents.46 In agreement, sevelamer was associated with less
progression of vascular calcification compared with tradi-
tional phosphate-lowering agents in the RIND study.47
Sevelamer treatment was also associated with reduced
all-cause mortality in the RIND study.48 In contrast, the
DCOR study did not show overall survival benefit of treat-
ment with sevelamer.49 Cardiovascular mortality remained
SILBERNAGEL ET AL68unchanged by sevelamer in the RIND and DCOR
studies.48,49
Combinations of Cholesterol-Lowering
Agents Affecting Intestinal Cholesterol
Metabolism
The addition of ezetimibe to a bile-acid-resin-based
regimen reduced LDL cholesterol by another 19%.50
Moreover, the addition of plant sterols in patients receiving
ezetimibe resulted in a further reduction of LDL choles-
terol of approximately 7%.38 The effects of combination
therapies of sevelamer with plant sterols, ezetemibe, or
bile acid resins on lipids have, to our knowledge, not
been tested so far in randomized controlled trials.
Cholesterol Homeostasis in End-Stage
Renal Disease
Two recent studies have investigated cholesterol homeo-
stasis in patients on maintenance hemodialysis treat-
ment.51,52 Rogacev and colleagues found that 113 people
on hemodialysis had higher cholesterol absorption and
lower cholesterol synthesis compared with 220 controls.51
Fukushima and colleagues similarly reported increased
cholesterol absorption in 94hemodialysis patients compared
with 58 controls.52 Rogacev and colleagues also made the
interesting observation that hemodialysis patients with
increased cholesterol absorptionmay have increasedmortal-
ity compared with those with low cholesterol absorption.51
Although both studies were small and need replication in
larger cohorts, they indicate that patients on chronic hemo-
dialysismay profit from inhibition of cholesterol absorption.
Dietary Strategies to Reduce Circulating
Cholesterol in Chronic Hemodialysis
There is broad evidence that high dietary cholesterol
intake is associated with increased circulating cholesterol
and higher risk for cardiovascular death.53 Moreover, die-
tary interventions that include lowering cholesterol intake
have been shown to reduce LDL cholesterol25,26 and to
prevent cardiovascular complications.54 It is likely that
particularly people with high cholesterol absorption may
be vulnerable to a diet rich in cholesterol. This may apply
to people on chronic hemodialysis.51,52 In agreement,
prehemodialysis dietitian care was associated with lower
circulating cholesterol and reduced mortality during the
first year of dialysis in a cohort of 156,440 patients.55
Khoueiry and colleagues performed a study using food fre-
quency questionnaires to estimate the dietary habits of peo-
ple on chronic hemodialysis in a U.S. outpatient dialysis
unit.56 They found that most people did not follow many
of the dietary recommendations of the American Heart As-
sociation for reducing the risk of cardiovascular disease.56
However, cholesterol intake was surprisingly low, which
may already indicate good compliance of the patientswith dietary advice to reduce cholesterol intake.56 Ap-
proaches to further reduce LDL cholesterol in hemodialysis
patients will thus have to go beyond dietary counseling.Plant Sterols and Stanols for Lipid
Lowering in Hemodialysis Patients
Dietary intake of plant sterols has been known to reduce
LDL cholesterol since the 1950s.57 In the 1990s, the use of
plant sterols and stanols became popular because they could
then be incorporated into various foods such as spreads and
dairy foods.58 The regular intake of foods containing
approximately 2 g of plant sterols or stanols is associated
with a decrease in LDL cholesterol of approximately
10% to 13%.27,28 Therefore, the use of plant sterols and
stanols has been recommended by the American Heart
Association.59 Moreover, the European Society of Cardiol-
ogy and the European Atherosclerosis Society have sug-
gested that foods enriched with plant sterols may be
considered for individuals with elevated total and LDL
cholesterol values in whom the total cardiovascular risk
assessment does not justify the use of a cholesterol-
lowering drug.60 Because they interfere with cholesterol
absorption, plant sterols and stanols may be considered
helpful in the treatment of hypercholesterolemia in chronic
hemodialysis patients. Despite the marked decrease of LDL
cholesterol, there is still a debate onwhether the use of plant
sterols and stanols is safe.58 These concerns are primarily
based on the association of sitosterolemia with an early
onset of cardiovascular disease.39 Sitosterolemia is a very
rare genetic disorder caused by mutations in the ABCG5
and ABCG8 genes.39 It is characterized by tendon and tis-
sue xanthomas and approximately 50-fold elevated serum
plant sterol levels.39 In contrast to sitosterolemic patients,
frequent users of plant-sterol-enriched foods only have
modestly increased circulating plant sterols.61 A recent
meta-analysis has shown that moderately elevated circu-
lating plant sterols are not associated with increased cardio-
vascular risk.62 The associations of common variants in the
ABCG8 and ABO genes with cardiovascular disease63-65
most probably are not mediated by elevated plant sterol
levels, either.15 Rather, high cholesterol absorption causes
an increase in cardiovascular risk.15 Large-scale clinical
studies testing for associations between circulating plant ste-
rols on cardiovascular risk are currently not available in pa-
tients with end-stage renal disease. These data may help to
further elucidate whether the use of plant sterols and stanols
is safe in these patients.Interpretation of the 4D, AURORA, and
SHARP Trial Results With a Focus on
Cholesterol Homeostasis
Statins did not significantly reduce major cardiovascular
events in the 4D and AURORA trials.11,12 According to
Rogacev and colleagues and Fukushima and colleagues,
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sterols.51,52 These observations may partly explain why
treatment with statins was not as successful as expected in
end-stage renal disease.11,12 On the other hand, these
observations suggest that patients on chronic hemodialysis
may potentially profit from cholesterol absorption in-
hibitors. The SHARP study has investigated the effect of
ezetimibe plus simvastatin treatment on major cardio-
vascular events compared with placebo in chronic kidney
disease.66 In the entire cohort of 9,270 participants, the
combination therapy significantly reduced atherosclerotic
events during a median follow-up of 4.9 years.66 Although
no such benefit could be observed in the subgroup of 3,023
patients on hemodialysis, the study supports beneficial
effects of ezetimibe treatment on atherogenesis in renal dis-
ease.66 An alternative explanation why the combination of
simvastatin and ezetimibe was effective in reducing cardio-
vascular risk in the SHARP study could be the fact that eze-
timibe reduces the intestinal absorption not only of
cholesterol and plant sterols but also of atherogenic
oxidized sterols.67,68
Conclusions
Summing up, there is some evidence that inhibition of
cholesterol absorption may be beneficial to cardiovascular
health in hemodialysis patients.32,33,51,52 Keeping a healthy
diet will decrease LDL cholesterol, but the achievable
reductions may be not strong enough with this single
approach. The SHARP study showed that treatment
with the cholesterol absorption inhibitor ezetimibe plus
simvastatin prevents major cardiovascular events in patients
with chronic kidney disease who were partly on hemo-
dialysis.66 However, SHARP did not prove that particularly
ezetimibewill preventmajor vascular events.66 Indeed, there
is some evidence that treatment with sevelamer is beneficial
to cardiovascular health in patients onhemodialysis.46-48The
efficacyof plant-sterol- and stanol-enriched functional foods
and bile acid resins to prevent atherosclerosis has not been
tested in the setting of chronic hemodialysis.
Perspectives
1) Future studies should address the scientific question
whether cholesterol absorption will predict the
effectiveness of statin treatment to reduce cardiovas-
cular risk in hemodialysis patients. Our hypothesis is
that hemodialysis patients with relatively low ab-
sorption of cholesterol might profit from statin treat-
ment. However, we expect those with relatively
high absorption to be mainly nonresponders.
2) It remains to be shown whether an association of
circulating plant sterols with vascular disease exists
in hemodialysis patients. If there is no association,
then this may argue against the atherogenic effects of
plant sterol supplementation in hemodialysis patients.Practical Application
Patients on chronic hemodialysis appear to have high
cholesterol absorption. Therefore, dietary counseling and
drugs that inhibit intestinal cholesterol absorption may be
instrumental to reduce cardiovascular risk in these patients.References
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